Pacing Lead Articles & Analysis

The company’s Tempo® Temporary Pacing Lead will be featured in a New Technology Forum discussion titled “Improved Temporary Transvenous Pacers: The BioTrace Tempo Lead,” presented by Steven Yakubov, M.D., System Chief, Advanced Structural Heart Disease at Riverside Methodist Hospital/OhioHealth. The discussion will highlight the performance and benefits of the Tempo Lead ...

By BioTrace Medical Inc

BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the Annual Transcatheter Valve Therapy Structural Heart Summit (TVT 2019), which will take place June 12-15 at the Sheraton Grand Chicago. The company’s Tempo Temporary Pacing Lead will be featured in a symposium titled “Improving Safety & Reducing ...

By BioTrace Medical Inc

BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s Tempo Lead has obtained CE Mark certification in Europe for use in cardiac procedures requiring temporary intracardiac pacing. BioTrace Medical’s Tempo Temporary Pacing Lead is designed for safer, more secure and stable pacing to reduce intraprocedural complications, ...

By BioTrace Medical Inc

BioTrace Medical, Inc., today announced the company’s key activities at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 meeting, which will take place October 29 - November 2 at the Colorado Convention Center in Denver. The company’s Tempo Temporary Pacing Lead will be featured in a breakfast symposium titled: “The Tempo Temporary Pacing Lead: A New Standard of Care in ...

By BioTrace Medical Inc

BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the 30th annual Transcatheter Cardiovascular Therapeutics (TCT) conference, which will take place September 21-25 in San Diego. BioTrace Medical’s innovative Tempo Temporary Pacing Lead is designed for secure and stable pacing with the goal of reducing ...

By BioTrace Medical Inc

BioTrace Medical, Inc., the leader in innovative temporary cardiac pacing technology, today announced the company’s Tempo Temporary Pacing Lead was featured in a patient case series presented at the Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting and Workshops, taking place virtually April 24-27. The series titled “A Case Series of the BioTrace Medical Tempo ...

By BioTrace Medical Inc

BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s key activities at the 31st annual Transcatheter Cardiovascular Therapeutics (TCT) conference, which will take place September 25-29 in San Francisco. The company’s Tempo Temporary Pacing Lead will be featured in a breakfast symposium titled “Keeping the Rhythm with the ...

By BioTrace Medical Inc

Published last month in the European Heart Journal, the case report details the successful deployment of the WiSE Electrode implanted in the LV septum of an 82-year-old male with tachyarrhythmia-induced cardiomyopathy. The patient exhibited improved electrical resynchronization on ECG and reported significant symptomatic improvement at six-month follow-up. This is the first reported case of ...

By EBR Systems, Inc.

EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced that Professor Pascal Defaye, Head of Rhythmology and Cardiac Stimulation Unit, CHU de Grenoble-Alpes, France, performed the world’s first successful Leadless Left Bundle Branch Area Pacing (LBBAP) implant performed utilizing the WiSE CRT System. LBBAP pacing has been ...

By EBR Systems, Inc.

EBR Systems, Inc., developer of the world's only wireless cardiac pacing system for heart failure, today announced that Dr. Mary Norine "Minnow" Walsh has become Co-Principal Investigator (Co-PI) of the SOLVE CRT clinical study. The SOLVE CRT (Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy) clinical study is a prospective randomized, double blinded pivotal ...

By EBR Systems, Inc.

EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the WiSE CRT System for the treatment of heart failure. The FDA created this designation and its associated program in 2017 for certain devices providing more effective treatment ...

By EBR Systems, Inc.

EBR Systems, Inc., developer of the world's only wireless cardiac pacing system for heart failure, today announced it has closed $30M in new funding to complete enrollment of its pivotal SOLVE CRT clinical trial and to prepare for commercialization of the WiSE Cardiac Resynchronization Therapy (CRT) System. This financing was led by Australian private equity firms Brandon Capital Partners and ...

By EBR Systems, Inc.

EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced enrollment of the first patients in the global SOLVE-CRT (Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy) clinical trial. The first patients were enrolled by Prof. Dr. Christian Butter at Immanuel Klinikum Herzzentrum Brandenburg in ...

By EBR Systems, Inc.

EBR Systems, Inc., developer of the world's only wireless cardiac pacing system for heart failure, today announced that the College of the French National Authority for Health (Haute Autorite de Sante, HAS) awarded a Forfait Innovation Package for the company's WiSE™ Cardiac Resynchronization Therapy (CRT) System. The award, worth up to €1 million, will help treat as many as 40 ...

By EBR Systems, Inc.

Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of a report documenting the clinical utility of the Surfacer System to gain venous access prior to the placement of cardiac resynchronization therapy (CRT) device leads in a patient with obstructed central veins. ...

By Bluegrass Vascular Technologies, Inc.

EBR Systems, Inc., developer of the world’s first and only wireless cardiac pacing system for heart failure, has raised $50 million to conduct the global SOLVE-CRT study. The financing was led by Australian private equity firms M.H. Carnegie & Co. and Brandon Capital Partners and included participation by prior investors Split Rock Partners, Ascension Ventures and Dr. Thomas ...

By EBR Systems, Inc.

EBR Systems’ WiSE™ CRT System is world’s first and only wireless endocardial (inside the heart) left ventricle pacing system for heart failure EBR’s AU$110m ASX initial public offering today was strongly supported by new and existing institutional shareholders The new capital funds the completion of pivotal study, targeting FDA submission for approval in 2023 followed ...

By EBR Systems, Inc.

Highlights: Dr Evans, Dr Steinhaus and Ms Drexler to join EBR Systems’ Board ahead of the planned A$110m IPO on the Australian Stock Exchange Board appointments follow the retirement of Mr Dave Stassen and Dr Leighton Read New EBR Systems’ Board consists of Mr Allan Will, Mr John McCutcheon, Dr Christopher Nave, Mr Trevor Moody, Dr Bronwyn Evans, Dr David Steinhaus and Ms ...

By EBR Systems, Inc.